Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
COMPENSATION 2026
ABOUT
PRICE TARGET
UPCOMING EARNINGS
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2019-12-27 | Reverse | 1:700 |
| 2019-12-24 | Reverse | 1:700 |
| 2019-10-22 | Reverse | 1:100 |
| 2018-05-02 | Reverse | 1:500 |
| 2017-11-06 | Reverse | 1:350 |
| 2016-07-21 | Reverse | 1:16 |
| 2014-04-09 | Reverse | 1:16 |
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$15.17 ▲ UP 0.86% (+$0.13)About Delcath Systems, Inc.
https://www.delcath.com ↗Delcath Systems, Inc. develops the HEPZATO KIT and CHEMOSAT system for targeted high-dose liver chemotherapy to treat primary and metastatic liver cancers in the U.S. and Europe.
INDUSTRY
A PRODUCT DELCATH SYSTEMS, INC. IS KNOWN FOR
HEPZATO KIT™ is an FDA-approved, targeted drug-device combo delivering high-dose melphalan directly to the liver to treat metastatic uveal melanoma, minimizing systemic side effects, with commercial launch in 2024.
Delcath Systems in 2025
Delcath Pivots to Platform Strategy with Initiation of Clinical Trials in New Cancer Indications
In 2025, Delcath Systems strategically shifted from a single-indication commercial entity to a broader oncology platform by initiating a global Phase 2 clinical trial for its HEPZATO KIT in liver-dominant metastatic colorectal cancer (mCRC) and advancing plans for a trial in metastatic breast cancer. This marks a pivotal expansion beyond its initial approved use in metastatic uveal melanoma, aiming to significantly enlarge its addressable market.
RATINGS SNAPSHOT
Overall rating: B-
MOST RECENT ANALYST GRADES
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 NVCR | $13.96 | COMPARE |
 AGL | $84.88 | COMPARE |
 MASS | $12.47 | COMPARE |
 TCMD | $22.27 | COMPARE |
 CERS | $2.36 | COMPARE |
 BWAY | $11.98 | COMPARE |
 NPCE | $13.06 | COMPARE |
 SENS | $9.96 | COMPARE |
TRADES BY CONGRESS
